[Using recombinant activated blood coagulation factor VII for treatment of hemorrhagic syndrome in patients with thrombocytopenia]

Anesteziol Reanimatol. 2014 Nov-Dec;59(6):60-6.
[Article in Russian]

Abstract

The review deals with an analysis of the use of recombinant activated factor clotting VII (rFVIIa) for the treatment of hemorrhagic syndrome in patients with thrombocytopenia. The review discusses cases of rFVIIa use during bleeding of different localization and different invasive interventions, a frequency of thrombotic complications and causes of the rFVlIIa insufficiency.

Publication types

  • Review

MeSH terms

  • Factor VIIa / administration & dosage
  • Factor VIIa / adverse effects
  • Factor VIIa / therapeutic use*
  • Hemorrhage / drug therapy*
  • Hemorrhage / etiology
  • Humans
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Syndrome
  • Thrombocytopenia / complications
  • Thrombocytopenia / drug therapy*

Substances

  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa